OCTOPLUS/LUMC BEGIN TRIALS FOR MIDDLE EAR INFECTION DRUG.
Middle ear infections and other infections of the upper airways often result in the presence of toxic microbial degradation products, so-called toxins, that remain at the site of infection. These toxins are unresponsive to traditional antibiotics and as a result chronic infections can occur. Often, surgical procedures are required to treat these infections. The new drug, developed by LUMC, has a novel mechanism of action; it neutralizes toxins at the site of infection and locally restores the body's natural clearance mechanism.
Middle ear infections are very common, affecting approximately 15% of all children. Given the mechanism of action of the drug, the potential exists to expand into other indications in the future, for example sinusitis and chronic bronchitis.
Clinical trials lead by Dr. Grote, Department of Otorhinolaryngology are in collaboration with Dr. Drijfhout, Department of Immunohematology and Blood Transfusion. "There is a clear need to develop novel therapies for infections of the upper airways to combat the increasing resistance against established antibiotics and to address chronic infections that do not respond well to current therapies," said Grote.
Joost Holthuis, CEO of OctoPlus, said, "We are very pleased to work with the LUMC as a strong clinical partner and look forward to first patient data on safety and efficacy of this novel compound."
OctoPlus OctoPlus is a product-oriented drug delivery company that focuses on the development of innovative drug delivery systems to build a pipeline of product candidates. OctoPlus is also an internationally established provider of pharmaceutical development services and GMP manufacturing for pharmaceutical and biotechnology companies. The company is located in Leiden, The Netherlands.
For more information, visit http://www.octoplus.nl.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 1, 2004|
|Previous Article:||ENZON/INEX SIGN COMMERCIALIZATION PACT FOR ONCOLOGY DRUG ONCO TCS.|
|Next Article:||EUROPEAN COMMISSION APPROVES ZEVALIN RADIOIMMUNOTHERAPY.|